Dashboard
Manage Tickers

COCP


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
09/15/2025 12:10:36

cocrystal-pharma-reveals-up-to-13m-registered-direct-offering
Cocrystal Pharma Reveals Up To $13M Regist...
09/12/2025 13:53:26

BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (NASDAQ:COCP) (the "Company" or "Cocryst...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
09/12/2025 12:09:50

cocrystal-pharma-highlights-cdi-988-as-first-oral-antiviral-candidate-for-norovirus-at-9th-international-calicivirus-conference
Cocrystal Pharma Highlights CDI-988 As Fir...
09/12/2025 12:02:56

Cocrystal Pharma, Inc. (NASDAQ:COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and c...

cocrystal-pharma-receives-study-may-proceed-letter-from-fda-to-conduct-phase-1b-challenge-study-evaluating-cdi-988-for-prevention-and-treatment-of-norovirus-infections-phase-1b-challenge-study-is-planned-to-begin-before-year-end-2025
Cocrystal Pharma Receives Study May Procee...
09/08/2025 12:01:58

There are currently no approved vaccines or treatments for norovirus infectionCocrystal's CDI-988 is the first antiviral fo...

cocrystal-pharma-q2-eps-020-beats-030-estimate
Cocrystal Pharma Q2 EPS $(0.20) Beats $(0....
08/14/2025 12:13:48

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0....

cocrystal-pharma-presents-phase-1-results-for-pan-viral-inhibitor-cdi-988-at-dod-medical-conference-including-that-all-cdi-988-doses-ranging-from-100-mg-to-1200-mg-in-phase-1-study-were-well-tolerated-company-expects-to-initiate-phase-1b-study-with-cdi-988-in-norovirus-infected-healthy-subjects-later-this-year
Cocrystal Pharma Presents Phase 1 Results ...
08/05/2025 12:05:15

All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well toleratedCompany expects to initiate Phase 1b...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/31/2025 21:07:05

cocrystal-pharma-presents-phase-1-study-data-of-first-in-class-norovirus-protease-inhibitor-cdi-988-at-9th-international-calicivirus-conference
Cocrystal Pharma Presents Phase 1 Study Da...
07/10/2025 12:13:47

hc-wainwright--co-maintains-buy-on-cocrystal-pharma-lowers-price-target-to-6
HC Wainwright & Co. Maintains Buy on Cocry...
06/20/2025 11:16:55

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cocrystal Pharma (NASDAQ:COCP) with a Buy and lowers the price ...

cocrystal-pharmas-recent-virology-study-shows-broad-spectrum-influenza-pb2-inhibitor-cc-42344-exhibits-strong-antiviral-activity-against-highly-pathogenic-h5n1-avian-influenza-a-strain
Cocrystal Pharma's Recent Virology Study S...
05/29/2025 12:03:30

CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strainThe Company's vi...

cocrystal-pharma-q1-eps-023-beats-051-estimate
Cocrystal Pharma Q1 EPS $(0.23) Beats $(0....
05/15/2025 12:18:35

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0....

cocrystal-pharma-announces-norovirus-oral-antiviral-candidate-demonstrates-potent-activity-against-the-emerging-gii17-variants
Cocrystal Pharma Announces Norovirus Oral ...
04/24/2025 12:01:54

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in ...

hc-wainwright--co-reiterates-buy-on-cocrystal-pharma-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Cocr...
01/22/2025 12:54:56

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:COCP) with a Buy and maintains $7 pri...

cocrystal-pharma-reports-phase-1-results-with-oral-broad-acting-antiviral-drug-cdi-988-for-prophylaxis-and-treatment-of-norovirus-coronaviruses-and-other-viral-infections-data-show-favorable-safety-and-tolerability-with-dosing-up-to-800-mg-for-10-days-plans-to-initiate-human-challenge-study-in-2025-in-norovirus-infected-subjects
Cocrystal Pharma Reports Phase 1 Results W...
01/08/2025 13:12:06

Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study in 2025...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
12/31/2024 21:05:53

dow-dips-over-100-points-cocrystal-pharma-shares-slide
Dow Dips Over 100 Points; Cocrystal Pharma...
12/31/2024 19:21:35

crude-oil-rises-1-sangamo-therapeutics-shares-plummet
Crude Oil Rises 1%; Sangamo Therapeutics S...
12/31/2024 17:01:49

us-stocks-open-higher-house-prices-increase-in-october
US Stocks Open Higher; House Prices Increa...
12/31/2024 15:02:31

cocrystal-pharma-plans-to-extend-phase-2a-influenza-challenge-study-with-oral-pb2-inhibitor-cc-42344-due-to-low-influenza-infection-among-challenged-participants
Cocrystal Pharma Plans To Extend Phase 2a ...
12/31/2024 13:03:11

"While CC-42344 showed a favorable safety and tolerability profile, we're disappointed by the low infectivity rate of t...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION